Submitted:
26 April 2024
Posted:
28 April 2024
You are already at the latest version
Abstract
(1) Background: The RDW-CV has predictive value in many pregnancy-related conditions. Re-search question: Can the RDW-CV be utilized predictively in pregnant patients with thrombo-philia? Aim of the study: To carry out a detailed analysis of the RDW-CV in pregnant patients with treated thrombophilia as compared with pregnant patients without thrombophilia who de-livered via cesarean section at term. (2) Methods: We studied 160 pregnant patients, including 80 pregnant patients with treated thrombophilia in the study group, and another 80 patients of a similar age and parity. The patients were referred to our hospital for delivery at term by means of a cesarean section between 1/10/2017 and 1/12/2021. Every patient received a sonogram during the first 1–2 days after the cesarean section, and their uterine evaluation was interpreted using the PUUS (Postpartum Uterine Ultrasonographic Scale). (3) Results: Our PUUS≥1 pregnant and postpartum patients with treated thrombophilia were the only group with an RDW-CV value over 14. No deep vein thrombosis was observed during hospitalization, showing that the antico-agulant treatment was necessary and effective. An RDW-CV of 14.5 was the highest value in the Rh-negative group of pregnant patients with treated thrombophilia. An RDW-CV of 14.48 was the highest level in the Rh-negative postpartum patients with treated thrombophilia. (4) Conclu-sion: An RDW-CV of ≥14 can predict uterine hematometra (PUUS≥1). The RDW-CV values were higher in Rh-negative patients.
Keywords:
RDW-CV
; thrombophilia
; pregnancy
; cesarean section
; Rh-factor
; postpartum
; uterine
; ultrasonography
; scale
1. Introduction
The RDW-CV has predictive value in many pregnancy-related conditions (preeclampsia, recurrent pregnancy loss, preterm labor, anemia, gestational diabetes). The red blood cell distribution width is calculated as the standard deviation of the erythrocyte volume (RDW-SD) divided by the mean corpuscular volume, times one thousand (RDW-CV). The values of the RDW-CV vary during the three trimesters of pregnancy and can change in conditions like recurrent pregnancy loss, preterm labor, preeclampsia, or anemia [1].
In preeclampsia patients, the values of the RDW-CV are markedly higher than those in healthy pregnant patients [2,3,4,5]. RDW levels are significantly increased in patients with severe preeclampsia when compared to patients with mild preeclampsia [6,7]. The RDW is also increased in potential preterm labor patients [8], and in patients with previous pregnancy loss [9,10].
The RDW is significantly higher in maternal blood from COVID-19 seropositive anemic pregnant women compared to seronegative pregnant women, and it is associated with COVID-19-related hypoxia [11,12,13,14,15]. After treatment for anemia, the RDW-SD value increased in pregnant women [16,17]. The RDW-SD, but not the RDW-CV, can be used as a diagnostic index of iron deficiency anemia for pregnant women [18,19].
At low altitudes, the RDW increases with the gestational trimester and is higher than that in non-pregnant women [20], while at high altitudes, the RDW does not change [21]. In acute pancreatitis in pregnancy, the RDW is also markedly elevated and is predictive of severity [22,23].
The aim of this work was to study whether there was any difference in the RDW-CV values in pregnant patients with treated thrombophilia as compared with pregnant patients without thrombophilia who delivered via cesarean section at term.
2. Materials and Methods
We included 160 pregnant patients in this study, with 80 pregnant patients with treated thrombophilia in the study group, and another 80 patients of a similar age and parity. The patients were referred to our hospital for delivery at term by means of a cesarean section between 1/10/2017 and 1/12/2021. Hospital policy required that patients already diagnosed with thrombophilia be provided a cesarean section at 38 weeks gestational age, and these patients comprised the study group. This was a prospective study. All of the patients with thrombophilia already had established diagnoses. Treatment with low-molecular-weight heparin was ongoing. Thrombophilia screening tests were not available at the study hospital; thus, the control group had their blood sent for screening to specialized laboratories, and were included following a negative result. The exclusion criteria were as follows: patients suffering from thrombocytopenia (n=2), patients with deep vein thrombosis (n=0), and patients with cerebral thrombosis (n=0) [24].
Table 1.
Thrombophilia mutations identified in the study group [24].
Table 1.
Thrombophilia mutations identified in the study group [24].
| Thrombophilia mutations identified in the study group | Number | Percent |
|---|---|---|
| Gene MTHFR | 43 | 53.75% |
| Factor V Leiden | 17 | 21.25% |
| Plasminogen activator inhibitor | 11 | 13.75% |
| Protein C | 4 | 5.00% |
| Prothrombin G20210A | 3 | 3.75% |
| Lupus anticoagulants | 1 | 1.25% |
| Antithrombin | 1 | 1.25% |
| TOTAL | 80 | 100% |
MTHFR = methylene tetrahydrofolate reductase.
There were no thrombophilia mutations identified in the control group (Table 2).
Every patient received a sonogram during the first 1–2 days after cesarean section, and the uterine evaluation was interpreted with the PUUS (Postpartum Uterine Ultrasonographic Scale). This scale [25,26] counts the quarters of missing uterine vacuum lines, which could be due to the presence of blood or debris, as follows:
In grade 0, the uterine cavity is completely empty.
In grade 1, there is a small amount of blood or debris occupying less than one-quarter of the vacuum line.
In grade 2, there is a slightly larger amount of blood or debris occupying less than two-quarters of the vacuum line.
In grade 3, there is a large amount of blood or debris occupying less than three-quarters of the vacuum line.
In grade 4, there is a large amount of blood or debris occupying more than three-quarters of the vacuum line [25,26].
In these cases, debris means that there could be blood or retained trophoblastic tissue. Blood is mobile and has no Doppler signal, while retained trophoblastic tissue is not mobile, is delineated in one or more areas, and has a Doppler signal. In this group of patients, none had retained trophoblastic tissue. We further referred to this debris as “uterine haematometra”.
In a previous study [24] on the same group of patients, we presented the demographic, maternal, and fetal outcomes.
The values and characteristics of the patients’ blood following analysis were extracted from the hospital’s medical records. For this study, the complete blood count values—the first count was obtained antepartum and the last count was obtained postpartum—were considered. Hospital policy required blood analyses both 24 hours before and after labor.
We performed the blood analysis using MAN-HEMATO laboratory equipment.
We performed the data analysis using SPSS version 18 (PASW Statistics for Windows, Chicago: SPSS Inc., Chicago, IL, USA). We determined the mean and median values, standard deviations, and quartiles. We also used the nonparametric Mann–Whitney U test and Spearman’s correlation. We considered p<0.05 to indicate significance [24].
3. Results
One patient with thrombophilia had incomplete data; thus, she was removed from this study, leaving 79 patients with thrombophilia and 80 patients without thrombophilia. All pregnant patients were at term.
3.1. Pregnant Patients
As shown previously [24], there was no significant difference between the simple values of the RDW-CV in pregnant patients with treated thrombophilia compared to those without. We further aimed to elucidate whether there was any difference in the involution of the uterine cavity postpartum, using the PUUS. Because we had few patients with PUUS grade 1–4, and we could not perform a detailed comparison with grade 1 or 2 or 3 in the group with treated thrombophilia as compared to the non-thrombophilia group, we considered PUUS≥1 to indicate any uterine cavity that did not close during the first 48 hours postpartum, and we compared these with uterine cavities that did close, designated PUUS=0, to simplify comparison between two groups of PUUS=0 and PUUS≥1 and their values for the RDW-CV.
There was no significant difference between the RDW-CV values in patients whose uterine cavities closed in the first 48 hours (PUUS=0) as compared to those whose did not (PUUS≥1), neither in pregnant patients with treated thrombophilia nor in the non-thrombophilia patients (Table 4). However, the PUUS≥1 pregnant patients with treated thrombophilia were the only group with RDW-CV≥14.
There was a weak negative correlation between the RDW-CV and age in the non-thrombophilia pregnant patients (Table 5): the RDW-CV decreased with the increasing age of the pregnant patient.
There was no correlation between the RDW-CV and number of gestations of the patients (Table 6).
There were no significant differences in the RDW-CV values of the four ABO blood groups (Table 7). There was no correlation between the RDW-CV and the ABO blood group.
There was no significant difference between the RDW-CV in the two Rh blood groups (Table 8). There was no correlation between the RDW-CV and the Rh blood groups. However, the Rh-negative pregnant patients with treated thrombophilia had the highest value of the RDW at 14.5.
Then, we calculated the correlation coefficient between the RDW-CV and maternal features (height, weight, body mass index) (Table 9). There was a weak correlation between the RDW-CV and BMI in the pregnant patients with treated thrombophilia (Table 9), indicating that the RDW-CV increased with increasing BMI among the pregnant patients with treated thrombophilia.
BMI=body mass index.
Then, we calculated the correlation coefficient between the RDW-CV and fetal outcomes (fetal weight, Apgar score) (Table 10). There was no correlation between the fetal outcomes and RDW-CV values.
3.2. Postpartum Patients
After calculating the above values, for the antepartum patients, we determined whether there was any correlation between the postpartum RDW-CV values and other values. Although the distribution was significantly different from normal (Table 11), there was no significant difference between the RDW-CV values in the two groups.
There was no significant difference between the postpartum RDW-CV values in patients whose uterine cavities closed in the first 48 hours (PUUS=0) as compared to those whose did not (PUUS≥1), neither in the postpartum patients with treated thrombophilia nor in the non-thrombophilia patients (Table 12). The PUUS grade did not depend on the RDW-CV.
There was a weak negative correlation between the postpartum RDW-CV and age in the non-thrombophilia postpartum patients (Table 13), indicating that the RDW-CV decreased with increasing age among the non-thrombophilia postpartum patients.
There was no correlation between the postpartum RDW-CV and number of gestations of the patients (Table 14).
There was no significant difference between the postpartum RDW-CV values in the four ABO blood groups (Table 15). There was no correlation between the postpartum RDW-CV and the ABO blood group.
There was no significant difference between the postpartum RDW-CV in the two Rh blood groups (Table 16). There was no correlation between the postpartum RDW-CV and the Rh blood group.
There was a weak correlation between the postpartum RDW-CV and BMI in the postpartum patients with treated thrombophilia (Table 17), indicating that the postpartum RDW-CV increased with increasing BMI in the postpartum patients.
There was no correlation between the fetal outcomes and postpartum RDW-CV values (Table 18).
4. Discussion
The RDW-CV demonstrates anisocytosis [27]. The higher the RDW-CV value, the more serious the anisocytosis. The RDW-CV increases in many diseases. A decreased value means that the cells are mostly uniform in size.
Red blood cells transport oxygen. In hypoxia-generating situations, red blood cells change shape, flexibility, dimensions, and adherence. Pregnancy generates hypoxia. In patients with pre-existing thrombophilia, pregnancy will favor the variability of the red blood cell dimensions, represented by the RDW-CV, and will also increase hypercoagulability, or thrombophilia. In recent years, increasingly developed proteomics and metabolomics technologies have become powerful tools for studying mature enucleated erythrocytes, significantly contributing to clarifying how hypoxia affects erythrocytes [28]. The shunt of the glycolysis pathway in oxygen transport is also involved in erythrocyte metabolism, and the deformability of erythrocytes influences erythrocyte aggregation and adhesion [28]. Red blood cells have a specific metabolomic signature in patients with a confirmed diagnosis of deep vein thrombosis or pulmonary embolism that distinguishes them from other acutely diseased patients, as represented by 20 significantly higher metabolites and four lower metabolites [29]. Three months after venous thromboembolism, plasma metabolomic profiling identified 512 metabolites, forming 62 biological clusters, while multivariate analysis revealed a panel of 21 metabolites capable of predicting venous thromboembolism status [30].
Febra [31] demonstrated a significant association between an early high RDW and the diagnosis of acute unprovoked deep vein thrombosis. An RDW of ≥14% was an independent predictor of unprovoked venous thromboembolism in adult patients. Our PUUS≥1 pregnant patients with treated thrombophilia had an average RDW of 14.06 (Table 4), and they were the only group with an RDW value over 14. The postpartum group, like the postpartum patients with treated thrombophilia, had an RDW-CV of 14.04 (Table 12), and remained the only group with an RDW-CV over 14, even after delivery. Nevertheless, they showed no deep vein thrombosis during hospitalization, suggesting that their anticoagulant treatment was necessary and effective.
An RDW-CV of 14.5, the highest value, occurred in the Rh-negative pregnant patients with treated thrombophilia (Table 8), indicating that Rh-negative is a potential predictor of deep vein thrombosis in pregnant patients with thrombophilia. An RDW-CV of 14.48 was the highest value in the postpartum group, occurring specifically in the Rh-negative postpartum patients with treated thrombophilia, and an RDW-CV of 14.01 was the highest value in the Rh-negative non-thrombophilia postpartum patients (Table 16).
There was a weak negative correlation between the RDW-CV and age in the non-thrombophilia pregnant patients; the RDW-CV decreased with increasing age of the pregnant patient. Anisocytosis decreased with increasing age of the pregnant patient, which has not been previously reported.
In pregnant women with obesity, the RDW is lower, indicating that a larger maternal body size during pregnancy generates more and smaller erythrocytes [32]. In our study, the RDW-CV increased with increasing BMI of the pregnant patients with treated thrombophilia and was not influenced by BMI in the non-thrombophilia pregnant patients, showing that either the condition or treatment of thrombophilia, associated with a higher BMI, generated anisocytosis.
5. Conclusions
Our PUUS≥1 pregnant patients with treated thrombophilia had an RDW of 14.06, and they were the only group with an RDW over 14. Postpartum, in the same patients with treated thrombophilia, the RDW-CV was 14.04, and they remained the only group with an RDW-CV over 14 even after delivery. However, no deep vein thrombosis was recorded during hospitalization, suggesting that their anticoagulant treatment was necessary and effective.
An RDW-CV of 14.5, the highest value, occurred in the Rh-negative pregnant patients with treated thrombophilia, indicating that Rh-negative status is a potential predictor of deep vein thrombosis in pregnant patients with thrombophilia. An RDW-CV of 14.48, the highest value postpartum, occurred in the Rh-negative postpartum patients with treated thrombophilia. An RDW-CV of 14.01 was obtained in the Rh-negative non-thrombophilia postpartum patients.
Author Contributions
Conceptualization, Catalina Filip and Roxana Covali; data curation, Ioana Sadyie Scripcariu and Tudor Butureanu; formal analysis, Ingrid Andrada Vasilache; funding acquisition, Catalina Filip; investigation, Mona Akad and Gabriela Dumachita-Sargu; methodology, Alexandru Carauleanu; project administration, Razvan Socolov; software, Lucian Vasile Boiculese; supervision, Razvan Socolov; validation, Demetra Socolov and Alina Melinte; visualization, Mona Akad; writing—original draft, Catalina Filip and Roxana Covali; writing—review & editing, Demetra Socolov and Alexandru Carauleanu. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Elena Doamna Obstetrics and Gynecology University Hospital (approval number 9 from September 17, 2017). .
Informed Consent Statement
Written informed consent has been obtained was obtained from all subjects involved in the study.
Data Availability Statement
Data from this study are available from the corresponding author upon reasonable request.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- Paliogiannis, P.; Zinellu, A.; Mangoni, A.A.; Capobianco, G.; Dessole, S.; Cherchi, P.L.; Carru, C. Red blood cell distribution width in pregnancy: a systematic review. Biochem. Medica 2018, 28, 030502. [Google Scholar] [CrossRef]
- Singhal, K.; Gupta, S.; Tiwari, S.; Pinjar, M.J. A Case-Control Study Utilizing Red Cell Distribution Width as a Bio-Inflammatory Marker in Pre-eclampsia. Cureus 2024, 16, e55910. [Google Scholar] [CrossRef] [PubMed]
- Kassahun, W.; Kidanewold, A.; Koira, G.; Biresaw, G.; Shiferaw, M. Hematological predictors of preeclampsia among pregnant women attending ante-natal clinic at Arba Minch General Hospital, South Ethiopia: A comparative cross-sectional study. Pr. Lab. Med. 2024, 39, e00362. [Google Scholar] [CrossRef]
- Ahenkorah, B.; Sakyi, S.A.; Fondjo, L.A.; Helegbe, G.; Owiredu, E.-W.; Der, E.M.; Amoah, L.E.; Kusi, K.A.; Obiri, D.; Amoani, B.; et al. Evaluating circulating soluble markers of endothelial dysfunction and risk factors associated with PE: A multicentre longitudinal case control study in northern Ghana. Heliyon 2023, 9, e19096. [Google Scholar] [CrossRef]
- Adam, I.; Mutabingwa, T.K.; Malik, E.M. Red cell distribution width and preeclampsia: a systematic review and meta-analysis. Clin. Hypertens. 2019, 25, 15. [Google Scholar] [CrossRef]
- Kurt, R.K.; Aras, Z.; Silfeler, D.B.; Kunt, C.; Islimye, M.; Kosar, O. Relationship of Red Cell Distribution Width With the Presence and Severity of Preeclampsia. Clin. Appl. Thromb. 2013, 21, 128–131. [Google Scholar] [CrossRef] [PubMed]
- Sachan, R.; Patel, M.L.; Vandana; Sachan, P. ; Shyam, R. Role of platelet count and mean platelet volume and red cell distribution width in the prediction of preeclampsia in early pregnancy. J. Fam. Med. Prim. Care 2021, 10, 838–843. [Google Scholar] [CrossRef]
- Tolunay, H.E.; Elci, E. Importance of haemogram parameters for prediction of the time of birth in women diagnosed with threatened preterm labour. J. Int. Med Res. 2020, 48. [Google Scholar] [CrossRef] [PubMed]
- Brito, R.d.S.; Barros, L.M.d.L.; Moreira, L.W.; Normando, R.N.; de Jesus, T.B.; Gonçalves, M.d.S.; Ramasawmy, R.; de Oliveira, S.F.; da Silva, K.E.R.; Fraiji, N.A.; et al. Basic biochemical and hematological parameters of structural hemoglobin variants in the postpartum women and their respective newborn from Manaus, Amazonas, Brazil. BMC Pregnancy Childbirth 2022, 22, 936. [Google Scholar] [CrossRef]
- Aynıoglu, O.; Isık, H.; Sahbaz, A.; Harma, M.I.; Isık, M.; Kokturk, F. Can Plateletcrit be a Marker for Recurrent Pregnancy Loss? Clin. Appl. Thromb. 2014, 22, 447–452. [Google Scholar] [CrossRef]
- Surekha, M.V.; Suneetha, N.; Balakrishna, N.; Putcha, U.K.; Satyanarayana, K.; Geddam, J.J.B.; Sreenu, P.; Tulja, B.; Mamidi, R.S.; Rutter, G.A.; et al. Impact of COVID-19 during pregnancy on placental pathology, maternal and neonatal outcome – A cross-sectional study on anemic term pregnant women from a tertiary care hospital in southern India. Front. Endocrinol. 2023, 14, 1092104. [Google Scholar] [CrossRef] [PubMed]
- Covali, R.; Socolov, D.; Pavaleanu, I.; Carauleanu, A.; Boiculese, V.L.; Socolov, R. SARS-CoV-2 Infection Susceptibility of Pregnant Patients at Term Regarding ABO and Rh Blood Groups: A Cohort Study. Medicina 2021, 57, 499. [Google Scholar] [CrossRef] [PubMed]
- Socolov, R.; Akad, M.; Păvăleanu, M.; Popovici, D.; Ciuhodaru, M.; Covali, R.; Akad, F.; Păvăleanu, I. The Rare Case of a COVID-19 Pregnant Patient with Quadruplets and Postpartum Severe Pneumonia. Case Report and Review of the Literature. Medicina 2021, 57, 1186. [Google Scholar] [CrossRef] [PubMed]
- Koç, E.M.E.; Fındık, R.B.; Akkaya, H.; Karadağ, I.; Tokalıoğlu, E. .; Tekin,.M. Comparison of hematological parameters and perinatal outcomes between COVID-19 pregnancies and healthy pregnancy cohort. jpme 2020, 49, 141–147. [Google Scholar] [CrossRef] [PubMed]
- Covali, R.; Socolov, D.; Socolov, R.; Pavaleanu, I.; Carauleanu, A.; Akad, M.; Boiculese, V.L.; Adam, A.M. Complete Blood Count Peculiarities in Pregnant SARS-CoV-2-Infected Patients at Term: A Cohort Study. Diagnostics 2021, 12, 80. [Google Scholar] [CrossRef] [PubMed]
- Schoorl, M.; Schoorl, M. Effects of iron supplementation on microcytic and hypochromic red blood cells during the third trimester of pregnancy. Int. J. Lab. Hematol. 2022, 44, 1060–1067. [Google Scholar] [CrossRef] [PubMed]
- Covali, R.; Socolov, D.; Socolov, R. Coagulation tests and blood glucose before vaginal delivery in healthy teenage pregnant women compared with healthy adult pregnant women. Medicine 2019, 98, e14360. [Google Scholar] [CrossRef]
- Kai, Y.; Ying, P.; Bo, Y.; Furong, Y.; Jin, C.; Juanjuan, F.; Pingping, T.; Fasu, Z. Red blood cell distribution width-standard deviation but not red blood cell distribution width-coefficient of variation as a potential index for the diagnosis of iron-deficiency anemia in mid-pregnancy women. Open Life Sci. 2021, 16, 1213–1218. [Google Scholar] [CrossRef]
- Akad, M.; Socolov, R.; Furnică, C.; Covali, R.; Stan, C.D.; Crauciuc, E.; Pavaleanu, I. Kisspeptin Variations in Patients with Polycystic Ovary Syndrome—A Prospective Case Control Study. Medicina 2022, 58, 776. [Google Scholar] [CrossRef]
- Alemu, A.; Abebe, M.; Terefe, B.; Yesuf, M.; Melku, M.; Enawgaw, B.; Biadgo, B. Hematological Indices of Pregnant Women at the University of Gondar Referral Hospital, Northwest Ethiopia: a Comparative Cross-Sectional Study. Clin. Lab. 2019, 65, 1431–1439. [Google Scholar] [CrossRef]
- Figueroa-Mujica, R.; Ccahuantico, L.A.; Ccorahua-Rios, M.S.; Sanchez-Huaman, J.J.; Vásquez-Velasquez, C.; Ponce-Huarancca, J.M.; Rozas-Gamarra, R.E.; Gonzales, G.F. A Critical Analysis of the Automated Hematology Assessment in Pregnant Women at Low and at High Altitude: Association between Red Blood Cells, Platelet Parameters, and Iron Status. Life 2022, 12, 727. [Google Scholar] [CrossRef] [PubMed]
- Liao, W.; Tao, G.; Chen, G.; He, J.; Yang, C.; Lei, X.; Qi, S.; Hou, J.; Xie, Y.; Feng, C.; et al. A novel clinical prediction model of severity based on red cell distribution width, neutrophil-lymphocyte ratio and intra-abdominal pressure in acute pancreatitis in pregnancy. BMC Pregnancy Childbirth 2023, 23, 189. [Google Scholar] [CrossRef] [PubMed]
- Jin, D.; Tan, J.; Jiang, J.; Philips, D.; Liu, L. The early predictive value of routine laboratory tests on the severity of acute pancreatitis patients in pregnancy: a retrospective study. Sci. Rep. 2020, 10, 10087. [Google Scholar] [CrossRef] [PubMed]
- Filip, C.; Covali, R.; Socolov, D.; Carauleanu, A.; Tanasa, I.A.; Scripcariu, I.S.; Ciuhodaru, M.; Butureanu, T.; Pavaleanu, I.; Akad, M.; et al. The postpartum uterine ultrasonographic scale in assessment of uterine involution after cesarean section in treated thrombophilia pregnant patients at term. J. Clin. Lab. Anal. 2022, 36, e24645. [Google Scholar] [CrossRef] [PubMed]
- Covali, R.; Socolov, D.; Socolov, R.V.; Akad, M. Postpartum Uterine Ultrasonographic Scale: a novel method to standardize the assessment of uterine postpartum involution. J. Med. Life 2021, 14, 511–517. [Google Scholar] [CrossRef] [PubMed]
- Covali, R.; Socolov, D.; Carauleanu, A.; Pavaleanu, I.; Akad, M.; Boiculese, L.V.; Socolov, R.V. The Importance of the Novel Postpartum Uterine Ultrasonographic Scale in Numerical Assessments of Uterine Involution Regarding Perinatal Maternal and Fetal Outcomes. Diagnostics 2021, 11, 1731. [Google Scholar] [CrossRef] [PubMed]
- Lippi, G.; Henry, B.M.; Mattiuzzi, C. Red blood cell distribution width (RDW) reflects disease severity in patients with carbon monoxide poisoning: systematic literature review and meta-analysis. Scand. J. Clin. Lab. Investig. 2024, 84, 79–83. [Google Scholar] [CrossRef] [PubMed]
- Jin, X.; Zhang, Y.; Wang, D.; Zhang, X.; Li, Y.; Wang, D.; Liang, Y.; Wang, J.; Zheng, L.; Song, H.; et al. Metabolite and protein shifts in mature erythrocyte under hypoxia. iScience 2024, 27, 109315. [Google Scholar] [CrossRef] [PubMed]
- Febra, C.; Saraiva, J.; Vaz, F.; Macedo, J.; Al-Hroub, H.M.; Semreen, M.H.; Maio, R.; Gil, V.; Soares, N.; Penque, D. Acute venous thromboembolism plasma and red blood cell metabolomic profiling reveals potential new early diagnostic biomarkers: observational clinical study. J. Transl. Med. 2024, 22, 200. [Google Scholar] [CrossRef]
- Fraser, K.; Roy, N.C.; Goumidi, L.; Verdu, A.; Suchon, P.; Leal-Valentim, F.; Trégouët, D.-A.; Morange, P.-E.; Martin, J.-C. Plasma Biomarkers and Identification of Resilient Metabolic Disruptions in Patients With Venous Thromboembolism Using a Metabolic Systems Approach. Arter. Thromb. Vasc. Biol. 2020, 40, 2527–2538. [Google Scholar] [CrossRef]
- Febra, C.; Spinu, V.; Ferreira, F.; Gil, V.; Maio, R.; Penque, D.; Macedo, A. Predictive Value for Increased Red Blood Cell Distribution Width in Unprovoked Acute Venous Thromboembolism at the Emergency Department. Clin. Appl. Thromb. 2023, 29. [Google Scholar] [CrossRef] [PubMed]
- Vega-Sánchez, R.; Tolentino-Dolores, M.C.; Cerezo-Rodríguez, B.; Chehaibar-Besil, G.; Flores-Quijano, M.E. Erythropoiesis and Red Cell Indices Undergo Adjustments during Pregnancy in Response to Maternal Body Size but not Inflammation. Nutrients 2020, 12, 975. [Google Scholar] [CrossRef] [PubMed]
Table 2.
Thrombophilia mutations in the control group [24].
Table 2.
Thrombophilia mutations in the control group [24].
| Thrombophilia mutations identified in the control group | Number | Percent |
|---|---|---|
| Gene MTHFR | 0 | 0% |
| Factor V Leiden | 0 | 0% |
| Plasminogen activator inhibitor | 0 | 0% |
| Protein C | 0 | 0% |
| Prothrombin G20210A | 0 | 0% |
| Lupus anticoagulants | 0 | 0% |
| Antithrombin | 0 | 0% |
| Protein S | 0 | 0% |
| Factor XIII V34L | 0 | 0% |
| Anticardiolipin antibodies | 0 | 0% |
| Antibeta-2-glycoprotein 1 antibodies | 0 | 0% |
| Antiphospholipid antibodies | 0 | 0% |
| TOTAL | 0 | 0% |
MTHFR = methylene tetrahydrofolate reductase.
Table 3.
Patient characteristics: mean, median, standard deviation, and quartile 1 and 2 values [24].
Table 3.
Patient characteristics: mean, median, standard deviation, and quartile 1 and 2 values [24].
| Patients | Thrombophilia patients (n = 80) |
Non-thrombophilia patients (n =80) |
Significance, p |
|---|---|---|---|
| Age (years) | 30 (±5) 30 (27–34) |
30 (±5) 30 (27–34) |
0.944 |
| Gestation (number) | 3 (±1) 3 (2–3) |
2 (±1) 2 (1–2) |
< 0.001 |
| Parity (number) | 2 (±1) 2 (1–2) |
2 (±1) 2 (1–2) |
0.213 |
The non-parametric Mann–Whitney test was used for comparisons.
Table 4.
The value of the RDW-CV in treated-thrombophilia patients and non-thrombophilia patients, with a closed uterine cavity within 24-48 hours (PUUS=0) or not (PUUS=1). The upper line represents the mean values with the standard deviation; the lower line represents the median values with quartiles 1 and 3.
Table 4.
The value of the RDW-CV in treated-thrombophilia patients and non-thrombophilia patients, with a closed uterine cavity within 24-48 hours (PUUS=0) or not (PUUS=1). The upper line represents the mean values with the standard deviation; the lower line represents the median values with quartiles 1 and 3.
| RDW-CV in pregnant patients with | PUUS=0 | PUUS≥1 | Significance, P |
|---|---|---|---|
| Treated thrombophilia | 13.77±1.60 13.51 (12.73; 14.65) |
14.06±1.77 14.02 (13.27; 14.26) |
.546 |
| Non-thrombophilia | 13.77±1.30 13.47 (12.84; 14.38) |
13.43±1.15 13.59 (13.19; 14.23) |
.917 |
PUUS, postpartum uterine ultrasonographic scale.
Table 5.
The correlation coefficients between the RDW-CV and age of the patients.
| Pregnant patients | Correlation coefficient | Significance, P |
|---|---|---|
| Treated thrombophilia | -0.11 | .30 |
| Non-thrombophilia | -0.288 | .009 |
Table 6.
The correlation coefficients between RDW-CV and number of gestation of the patients.
| Pregnant patients | Correlation coefficient | Significance, P |
|---|---|---|
| Treated thrombophilia | 0.10 | 0.34 |
| Non-thrombophilia | -0.06 | 0.57 |
Table 7.
The value of the RDW-CV in treated-thrombophilia patients and non-thrombophilia patients, according to ABO blood group. The upper line represents the mean values with standard deviations; the lower line represents the median values and the lowest line quartiles 1 and 3.
Table 7.
The value of the RDW-CV in treated-thrombophilia patients and non-thrombophilia patients, according to ABO blood group. The upper line represents the mean values with standard deviations; the lower line represents the median values and the lowest line quartiles 1 and 3.
| RDW-CV in pregnant patients with | OI | AII | BIII | ABIV | Significance, P |
|---|---|---|---|---|---|
| Treated thrombophilia | 14.00±1.65 | 13.53±1.41 | 14.05±1.93 | 14.26±1.85 | 0.818 |
| 13.70 (13.04; 14.53) |
13.29 (12.12; 14.47) |
13.38 (12.83; 15.35) |
13.58 (12.98; 16.22) |
||
| Non-thrombophilia | 13.58±1.23 | 13.75±1.19 | 14.00±1.83 | 13.56±0.97 | 0.952 |
| 13.42 (12.82; 14.30) |
13.58 (12.89; 14.33) |
12.96 (12.55; 15.53) |
13.19 (13.13; 13.88) |
Table 8.
The value of the RDW-CV in treated-thrombophilia patients and non-thrombophilia patients, according to the Rh blood factor. The upper line represents the mean values with standard deviations; the lower line represents the median values with quartiles 1 and 3.
Table 8.
The value of the RDW-CV in treated-thrombophilia patients and non-thrombophilia patients, according to the Rh blood factor. The upper line represents the mean values with standard deviations; the lower line represents the median values with quartiles 1 and 3.
| RDW-CV in pregnant patients with | Rh-positive | Rh-negative | Significance, P |
|---|---|---|---|
| Treated thrombophilia | 13.73±1.56 13.58 (12.76; 14.45) |
14.50±1.96 14.54 (12.77; 16.17) |
.291 |
| Non-thrombophilia | 13.70±1.29 13.48 (12.85; 14.30) |
13.90±1.17 13.68 (12.83; 14.84) |
.671 |
Table 9.
The correlation coefficients between the RDW-CV and maternal features.
| Pregnant patients | Feature | Correlation coefficient | Significance, P |
|---|---|---|---|
| Treated thrombophilia | Height Weight BMI |
-0.094 0.168 0.236 |
0.409 0.139 0.037 |
| Non-thrombophilia | Height Weight BMI |
0.140 0.117 0.039 |
0.215 0.302 0.731 |
Table 10.
The correlation coefficients between the RDW-CV and fetal outcomes.
| Pregnant patients | Fetal outcome | Correlation coefficient | Significance, P |
|---|---|---|---|
| Treated thrombophilia | Weight Apgar score |
0.203 -0.017 |
0.073 0.883 |
| Non-thrombophilia | Weight Apgar score |
0.176 -0.038 |
0.118 0.740 |
Table 11.
The value of the postpartum RDW-CV in treated-thrombophilia patients and non-thrombophilia patients.
Table 11.
The value of the postpartum RDW-CV in treated-thrombophilia patients and non-thrombophilia patients.
| RDW-CV in postpartum patients with | Mean RDW-CV |
Median RDW-CV |
Shapiro Wilk test significance |
|---|---|---|---|
| Treated thrombophilia | 13.97±1.78 | 13.61 (12.80; 14.68) | .001 |
| Non-thrombophilia | 13.77±1.33 | 13.47 (12.89; 14.54) | .001 |
There is significance. Distribution is different from normal.
Table 12.
The value of the postpartum RDW-CV in treated-thrombophilia patients and non-thrombophilia patients, whose uterine cavities closed within 24–48 hours (PUUS=0), or not (PUUS=1). The upper line represents the mean values with standard deviations; the lower line represents the median values with quartiles 1 and 3.
Table 12.
The value of the postpartum RDW-CV in treated-thrombophilia patients and non-thrombophilia patients, whose uterine cavities closed within 24–48 hours (PUUS=0), or not (PUUS=1). The upper line represents the mean values with standard deviations; the lower line represents the median values with quartiles 1 and 3.
| RDW-CV in postpartum patients with | PUUS=0 | PUUS=1 | Significance, P |
|---|---|---|---|
| Treated thrombophilia | 13.96±1.80 13.53 (12.72; 15.08) |
14.04±1.76 13.72 (13.11; 14.59) |
.765 |
| Non-thrombophilia | 13.80±1.37 13.26 (12.87; 14.55) |
13.60±1.13 13.67 (13.20; 14.40) |
.742 |
PUUS, postpartum uterine ultrasonographic scale.
Table 13.
The correlation coefficients between the postpartum RDW-CV and age of the patients.
| Postpartum patients | Correlation coefficient | Significance, P |
|---|---|---|
| Treated thrombophilia | -0.11 | 0.33 |
| Non-thrombophilia | -0.35 | 0.002 |
Table 14.
The correlation coefficients between the postpartum RDW-CV and number of gestations of the patients.
Table 14.
The correlation coefficients between the postpartum RDW-CV and number of gestations of the patients.
| Postpartum patients | Correlation coefficient | Significance, P |
|---|---|---|
| Treated thrombophilia | 0.05 | 0.62 |
| Non-thrombophilia | -0.05 | 0.64 |
Table 15.
The value of the postpartum RDW-CV in treated-thrombophilia patients and non-thrombophilia patients, according to ABO blood group. The upper line represents the mean values with standard deviations; the lower line represents the median values with quartiles 1 and 3.
Table 15.
The value of the postpartum RDW-CV in treated-thrombophilia patients and non-thrombophilia patients, according to ABO blood group. The upper line represents the mean values with standard deviations; the lower line represents the median values with quartiles 1 and 3.
| RDW-CV in postpartum patients with | OI | AII | BIII | ABIV | Significance, P |
|---|---|---|---|---|---|
| Treated thrombophilia | 14.10±1.69 | 13.73±1.79 | 14.23±2.01 | 14.29±1.78 | 0.751 |
| 13.67 (12.80; 14.83) |
13.26 (12.17; 14.67) |
13.52 (13.15; 15.55) |
13.58 (13.12; 16.17) |
||
| Non-thrombophilia | 13.66±1.30 | 13.76±1.26 | 14.06±1.91 | 13.73±1.07 | 1.000 |
| 13.48 (12.77; 14.50) |
13.57 (12.86; 14.53) |
13.14 (12.83; 15.20) |
13.22 (13.15; 14.57) |
Table 16.
The value of the postpartum RDW-CV in treated-thrombophilia patients and non-thrombophilia patients, according to the Rh blood factor. The upper line represents the mean values with standard deviations; the lower line represents the median values with quartiles 1 and 3.
Table 16.
The value of the postpartum RDW-CV in treated-thrombophilia patients and non-thrombophilia patients, according to the Rh blood factor. The upper line represents the mean values with standard deviations; the lower line represents the median values with quartiles 1 and 3.
| RDW-CV in postpartum patients with | Rh-positive | Rh-negative | Significance, P |
|---|---|---|---|
| Treated thrombophilia | 13.91±1.74 13.61 (12.80; 14.67) |
14.48±2.18 14.09 (12.42; 16.59) |
.566 |
| Non-thrombophilia | 13.76±1.35 13.47 (12.86; 14.53) |
14.01±1.25 13.78 (12.98; 14.81) |
.577 |
Table 17.
The correlation coefficients between the postpartum RDW-CV and maternal features.
| Postpartum patients | Feature | Correlation coefficient | Significance, P |
|---|---|---|---|
| Treated thrombophilia | Height Weight BMI |
-0.052 0.217 0.279 |
0.656 0.061 0.015 |
| Non-thrombophilia | Height Weight BMI |
0.108 0.132 0.076 |
0.365 0.269 0.525 |
BMI=body mass index.
Table 18.
The correlation coefficients between the postpartum RDW-CV and fetal outcomes.
| Postpartum patients | Fetal outcome | Correlation coefficient | Significance, P |
|---|---|---|---|
| Treated thrombophilia | Weight Apgar score |
0.154 -0.005 |
0.188 0.969 |
| Non-thrombophilia | Weight Apgar score |
0.225 -0.123 |
0.057 0.302 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
